Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Retifanlimab · Zynyz, INCMGA-00012

Monoclonal antibody · Inhibitor of programmed cell death protein 1 (PD-1) (PDCD1) · developed by Incyte

Approved FDA, Mar 2023
INCY Developer
1 Registered trials

What is Retifanlimab?

Retifanlimab is a humanized monoclonal antibody that binds the PD-1 receptor on T cells and blocks its interaction with the ligands PD-L1 and PD-L2, potentiating T-cell activity against tumors. It is studied in resectable sarcoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Zynyz, INCMGA-00012, MGA012, AEX-1188
Drug type
Monoclonal antibody
Targets
programmed cell death protein 1 (PD-1) (PDCD1)
Mechanism
Inhibitor of programmed cell death protein 1 (PD-1) (PDCD1)
Pathways
PD-1/PD-L1 immune checkpoint signaling, T-cell activation
Therapy area
Oncology
Developer
Incyte Corp (INCY)
FDA status
Approved as Zynyz (March 22, 2023), BLA761334 · FDA label
UNII
2Y3T5IF01Z

✅ FDA-approved uses

From the indications section of the FDA label (version of May 18, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04374305 Phase 2 Neurofibromatosis Type 2 Recruiting INCY

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Resectable Sarcoma

Other drugs acting on PDCD1

More from Incyte

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the INCY page.

Follow INCY, the company behind Retifanlimab

See INCY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

INCY catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.